HOME >> BIOLOGY >> NEWS
Acorda announces positive Phase 3 Fampridine-SR study in people with multiple sclerosis

Conference Call and Webcast at 8:30 am ET on September 25, 2006

Hawthorne, NY September 25, 2006 - Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced positive results from its Phase 3 clinical trial of Fampridine-SR on walking in people with multiple sclerosis (MS). Statistical significance was achieved on all three efficacy criteria defined in the Special Protocol Assessment (SPA) by the Food and Drug Administration (FDA). A significantly greater proportion of people taking Fampridine-SR had a consistent improvement in walking speed, the study's primary outcome, compared to people taking placebo (34.8 percent vs. 8.3 percent) as measured by the Timed 25-Foot Walk (p<0.001). In addition, the effect was maintained in this study throughout the 14-week treatment period (p<0.001) and there was a statistically significant improvement in the 12-Item MS Walking Scale (MSWS-12) for walking responders vs. non-responders (p<0.001).

The average increase in walking speed over the treatment period compared to baseline was 25.2 percent for the drug group vs. 4.7 percent for the placebo group. Increased response rate on the Timed 25-Foot Walk was seen across all four major types of MS. In addition, statistically significant increases in leg strength were seen in both the Fampridine-SR Timed Walk responders (p<0.001) and the Fampridine-SR Timed Walk non-responders (p=0.046) compared to placebo. The Company intends to present comprehensive data at an upcoming medical meeting.

"We are delighted with the results from this trial, which are consistent with Acorda's prior Phase 2 study in people with MS. We will request a meeting with the FDA as soon as possible to discuss next steps for the Fampridine-SR program," said Ron Cohen, M.D., President and CEO. "Acorda is committed to the development of therapies that will improve the function and lives of people with MS, and we wish to thank the physicians and people with MS who particip
'"/>

Contact: Erica Wishner, Acorda Therapeutics
ewishner@acorda.com
914-347-4300
Porter Novelli
25-Sep-2006


Page: 1 2 3 4 5

Related biology news :

1. Almac Diagnostics announces pioneering genetic research on ductal carcinoma in situ
2. ESA announces 2007 award recipients
3. President Bush announces 2005 and 2006 Laureates of National Medals of Science and Technology
4. Conservation Leadership Program announces 2007 awardees
5. ACMG Foundation announces 2007-2008 Luminex/ACMGF award recipient
6. Revolutionary global environment fund announces $50M expansion
7. Biovest announces interim blinded data of fast-tracked pivotal Phase 3 clinical trial of BiovaxID
8. Cell Press announces new partnership with the American Society of Human Genetics
9. ChemGenex announces publication confirming activity of Ceflatonin in T315I-Positive CML
10. Minister Lunn announces $39.6M for next phase of mountain pine beetle response
11. BioMed Central announces new interdisciplinary Biofuels Journal

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/3/2020)... ... 03, 2020 , ... Accumen Inc. is helping healthcare get ... Spectrum Solutions, to provide COVID-19 saliva testing kits nationally. , “Accumen has ... than 10 years. Early in the COVID-19 crisis, we identified supply chain gaps ...
(Date:7/22/2020)... , ... July 21, 2020 , ... ... transformation and innovation in technology and compliance, announces a new solution to manage ... must ensure every layer of their technology stack complies with FDA and global ...
(Date:7/10/2020)... , ... July 08, 2020 , ... ... Cell and Gene Therapy Regulation, An FDAnews Webinar, Wednesday, July 22, 2020 • ... comparability study, but what is the most effective way to complete one? Will ...
Breaking Biology News(10 mins):
(Date:7/10/2020)... , ... July 08, 2020 , ... ... and products, announces a significant expansion of laboratory operations through its COVID-19 ... agencies implementing testing programs. , Bode-CARES provides a turnkey solution ...
(Date:7/7/2020)... ... , ... R3 International is now offering stem cell therapy for Alzheimers dementia ... on the patient's condition, treatment may be offered IV, intrathecal or with a combination. ... Alzheimers dementia, and the incidence continues to increase as individuals live longer. There is ...
(Date:7/1/2020)... ... June 30, 2020 , ... ... announced that the launch of a new clinical diagnostics immuno-oncology service, ... tumor microenvironment (TME). , “Flagship’s TissueInsight is a service that aids pathologists, ...
(Date:6/28/2020)... ... June 26, 2020 , ... ... solutions providers, today announced its strong opposition to the recently introduced bicameral ... a blanket ban on most federal use of nearly all biometric and related ...
Breaking Biology Technology:
Cached News: